Company

Location

Amount (US$M)

Round

Details

Date

Total: $1,012.36M

Amal Therapeutics SA

Geneva

$9.5

Series B

8M (US$9.5M) in the first closing of a proposed 20M series B round; Amal's founding investors, Boehringer Ingelheim Venture Fund (Bivf) and the German public funder High Tech Grunderfonds, both followed on, and Bivf was joined by new investors Biomedpartners and Helsinn Investment Fund in leading the round; other new investors are VI Partners and Schroder Adveq

9/6/17

Autolus Ltd.

London

$80

Series C

$80M in a series C round from Cormorant Asset Management, Nextech Invest and additional undisclosed investors, as well as founding investor Syncona Ltd., Woodford Investment Management and Arix Bioscience plc

9/27/17

Bridgebio Pharma Inc.

Palo Alto, Calif.

$135

N/A

$135 million, with new investor Viking Global Investors and existing investor KKR co-leading the round, with participation from existing investor Perceptive Advisors and new investors AIG, Aisling Capital, Cormorant Capital and Janus Funds

9/14/17

Da Volterra SA

Paris

$23.9

N/A

20M (US$23.9M) loan from the European Investment Bank

9/25/17

Disarm Therapeutics Inc.

Cambridge, Mass.

$30

Series A

$30M led by Atlas Venture, with co-investors Lightstone Ventures and Abbvie Ventures

9/20/17

Discgenics Inc.

Salt Lake City

$14

Series B

$14M series B financing jointly led by the company's board, existing long-term investors and new investment partner and observer Mitsubishi UFJ Capital Co. Ltd.

9/27/17

Edesa Biotech Inc.

Markham, Ontario

$7

Series A

$7M in a series A round led by Lumira Capital, and including participation from Pharmascience Inc. and Inveready Technology Investment Group and a number of Canadian family offices

9/21/17

Eligo Bioscience SAS

Paris

$20

N/A

$20M in financing from Khosla Ventures, Seventure Partners and the French government-sponsored Worldwide Innovation Challenge

9/27/17

Engage Therapeutics Inc.

Summit, N.J.

$23

Series A

$23M series A financing round led TPG, joined by Adage Capital Management and Lumira Capital

9/28/17

Enlivex Therapeutics Ltd.

Jerusalem

$50

N/A

$8M equity financing round at a valuation of about $50M pre-closing; Korea Investment Partners invested $6M, and Hadasit Bio Holdings Ltd. co-invested $2M

9/20/17

Entasis Therapeutics Inc.

Waltham, Mass.

$31.9

Series B-1

$31.9M in a series B-1 extension financing, which adds Pivotal Bioventure Partners, Sofinnova Ventures and TPG Biotech to the original series B funding round of $50M, which closed in March 2016, led by Clarus and including Frazier Healthcare Partners, Novo A/S and Eventide Funds

9/6/17

Epivax Oncology Inc.

Providence, R.I.

$0.5

Seed

$500,000 in seed funding from Epivax Inc.

9/26/17

Excision Biotherapeutics Inc.

Philadelphia

$10

Seed

$10M seed round, led by Artis Ventures

9/7/17

Exicure Inc.

Skokie, Ill.

$20

N/A

$20M from existing investors, including Abbvie Ventures, Bill Gates, Groupon executive Eric Lefkofsky, former Microsoft Corp. executive Craig Mundie, the Rathmann Family Foundation, retired Aon CEO Patrick Ryan, and Illumina Inc. co-founder David Walt, as well as new investors led by Mark Tompkins and Katalyst Securities LLC

9/29/17

Fusion Pharmaceuticals Inc.

Hamilton, Ontario

$21

Series A

$21M in a series A second closing, raising a total of $46M; new investors are Adams Street Partners, Seroba Life Sciences and Varian Medical Systems Inc., who join existing investors FACIT, Genesys Capital, Healthcap, Johnson & Johnson and TPG Biotech

9/26/17

Go Therapeutics Inc.

Cambridge, Mass.

$5

N/A

$5M investment from Salubris Pharmaceutical Ltd., of Shenzhen, China

9/26/17

Greenlight Biosciences Inc.

Medford, Mass.

$18

Series D

$18M series D round of financing led by Fall Line Capital, S2G Ventures, Lewis and Clark Ventures and Macro Capital Investments, along with the majority of the company's existing investors, including Kodiak Venture Partners, MLSCF, Syngenta Ventures and others

9/14/17

Grid Therapeutics LLC

Durham, N.C.

N/A

Series A

Closed its series A financing led by Longview International Ltd., a Singapore-based venture capital firm

9/15/17

Gritstone Oncology Inc.

Emeryville, Calif.

$92.7

Series B

$92.7M series B round led by new investor Lilly Asia Ventures, with participation from GV (formerly Google Ventures), Trinitas Capital (Beijing) and Alexandria Venture Investments, all new investors; the existing investors, including Versant Ventures, the Column Group, Clarus Funds and Frazier Healthcare Partners, also participated

9/8/17

Immunic AG

Planegg-Martinsried, Germany

$11.9

Series A

€10M (US$11.9M) additional in series A round, taking the grand total to €31.7M

9/6/17

Immunocore Ltd.

Oxford, U.K.

$40

N/A

$40M through an investment from the Bill and Melinda Gates Foundation

9/19/17

Kaleido Biosciences Inc.

Bedford, Mass.

N/A

N/A

Flagship Pioneering said Kaleido has emerged from stealth mode and is capitalized with $65M

9/19/17

Landos Biopharma Inc.

Blacksburg, Va.

$10

Series A

$10M in a series A round from exclusive investor Perceptive Advisors LLC

9/22/17

Lifemine Therapeutics Inc.

Boston

$55

Series A

$55M series A led by Wuxi Healthcare Ventures, which was joined by Foresite Capital, GV (formerly Google Ventures), Arch Ventures, Boyu Capital, Blue Pool Capital, Merck Ventures and Alexandria Venture Investments

9/19/17

LNC Therapeutics

Bordeaux, France

$7.66

Series C

€6.5M (US$7.66M) series C round, co-led by Seventure Partners in conjunction with a consortium of existing investors and a family office

9/29/17

Notable Labs Inc.

San Francisco

$10

Series A

$10M series A financing, which raises total funding raised since 2014 to more than $17M; round was led by Builders VC, with participation from existing investors

9/7/17

Opsidio LLC

Bryn Mawr, Pa.

N/A

N/A

Closed on the first tranche of a bridge financing, led by Bioadvance and private investors

9/26/17

Prellis Biologics Inc.

San Francisco

$1.8

Seed

$1.8M seed investment led by True Ventures and joined by Civilization Ventures and 415 Ventures, along with angel investors

9/14/17

Replimmune Group Inc.

Woburn, Mass.

$55

Series B

$55M series B financing led by Foresite Capital who was joined by other new investors, including Bain Capital Life Sciences, Redmile Group, Cormorant Asset Management and entities affiliated with Leerink Partners; all of the company's existing investors – Atlas Venture, Forbion Capital Partners and Omega Funds – also participated

9/11/17

Rodin Therapeutics Inc.

Cambridge, Mass.

$27

N/A

$27M in a round from Atlas Venture, GV, Hatteras Venture Partners, Remeditex Ventures LLC and Third Point Ventures LLC

9/19/17

Specificit Pharma Inc.

Montreal

N/A

Seed

Seed financing by existing shareholder Amorchem, along with new partners Sanderling Ventures and Accel-Rx Health Sciences Accelerator

9/12/17

Thermalin Inc.

Cleveland

$17.5

Series A

First closing of a tranched series A preferred financing that will raise at least $17.5M; it is led by Sanofi SA, of Paris, with participation by JSRmblVC Lifescience Investment Ltd. (a Tokyo-based fund) and Green Park & Golf Ventures (a Dallas-based fund), along with Thermalin's existing investors, and other undisclosed investors

9/29/17

Tolremo Therapeutics AG

Zurich, Switzerland

$2.5

N/A

CHF2.4M (US$2.5M) from private investors

9/19/17

Wuxi Nextcode

Shanghai

$165

Series B

$165M in a $240-million series B funding round it started near the end of the first quarter; included investments from a consortium led by Sequoia China along with Temasek, Yunfeng Capital, 3W Partners, Amgen Ventures and other existing long-term investors and partners; China Renaissance Group is the sole financial advisor

9/11/17

XW Laboratories Inc.

Wuhan, China

$17.5

Series B

$17.5M series B round led by Elements Capital and WI Harper with participation from new investor KTB Network and all existing investors: Kleiner Perkins Caufield & Byers China, Johnson & Johnson Innovation - JJDC, Inc. and Wuxi Venture

9/21/17


Notes

Currency conversions are based on exchange rates at the time of the deal.

This chart includes only biotech companies that develop therapeutics.

 

No Comments